AVI BioPharma, Inc. (AVII) Tops Q3 EPS by 3c; Guides FY11 Sales
Tweet
Share
E-mailGet Alerts AVII Hot Sheet
Price: $0.66 --0%
Financial Fact:
Net income (loss) and comprehensive income (loss): -56.74M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Financial Fact:
Net income (loss) and comprehensive income (loss): -56.74M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
AVI BioPharma, Inc. (NASDAQ: AVII) reported Q3 EPS of ($0.03), $0.03 better than the analyst estimate of ($0.06).
Sees FY2011 revenue of $40-$50 million, versus the consensus of $54.18 million.
Sees FY2011 revenue of $40-$50 million, versus the consensus of $54.18 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- USCB Financial Holdings, Inc. (USCB) Tops Q1 EPS by 2c
- L3Harris Technologies (LHX) Tops Q1 EPS by 15c; raises guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
